학술논문
N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.
Document Type
Article
Author
Source
Subject
*CATHETERIZATION
*RADIOGRAPHY equipment
*HEART disease diagnosis
*KIDNEY diseases
*CLINICAL trials
CARDIAC surgery patients
*
*
*
*
Language
ISSN
1355-6037
Abstract
Objective: To evaluate oral N-acelylcysteine in the prevention of contrast induced nephropathy (CIN) in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality contrast medium. Methods: In a multicentre double blind clinical trial 156 patients undergoing coronary angiography or percutaneous coronary intervention with serum creatinine ⩾ 106.08 μmol/l or creatinine clearance <50 mI/min or diabetes mellitus were randomly assigned to receive N-acetylcysteine 600 mg orally twice daily for two days or placebo. Only low osmolality ionic contrast medium was used. Results: Sixteen patients developed CIN, defined as an increase of 44.2 μmol/l in creatinine in 48 hours: eight of 77 patients (10.4%) in the N-acetylcysteine group and eight of 79 patients (10.1 %) in the placebo group (p = 1.00). The mean (SD) change in serum creatinine was similar in both groups: 7.96 (35.36) pmol/l in the N-acetylcysteine group and 6.19 (25.64) μmol/l in the placebo group (p = 0.67). No difference was observed in the change in endogenous creatinine clearance (-0.54 (10.4) mI/min v -2.52 (12.3) mI/min N-acetylcysteine and placebo, respectively, p = 0.28). Conclusion: Oral N-acelylcysteine did not prevent CIN in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality contrast medium. [ABSTRACT FROM AUTHOR]